Halligan Steve, Lilford Richard J, Wardle Jane, Morton Dion, Rogers Pauline, Wooldrage Katherine, Edwards Rob, Kanani Reshma, Shah Urvi, Atkin Wendy
Department of Specialist Radiology, University College Hospital London, London, UK.
Trials. 2007 Oct 27;8:32. doi: 10.1186/1745-6215-8-32.
The standard whole-colon tests used to investigate patients with symptoms of colorectal cancer are barium enema and colonoscopy. Colonoscopy is the reference test but is technically difficult, resource intensive, and associated with adverse events, especially in the elderly. Barium enema is safer but has reduced sensitivity for cancer. CT colonography ("virtual colonoscopy") is a newer alternative that may combine high sensitivity for cancer with safety and patient acceptability. The SIGGAR trial aims to determine the diagnostic efficacy, acceptability, and economic costs associated with this new technology.
The SIGGAR trial is a multi-centre randomised comparison of CT colonography versus standard investigation (barium enema or colonoscopy), the latter determined by individual clinician preference. Diagnostic efficacy for colorectal cancer and colonic polyps measuring 1 cm or larger will be determined, as will the physical and psychological morbidity associated with each diagnostic test, the latter via questionnaires developed from qualitative interviews. The economic costs of making or excluding a diagnosis will be determined for each diagnostic test and information from the trial and other data from the literature will be used to populate models framed to summarise the health effects and costs of alternative approaches to detection of significant colonic neoplasia in patients of different ages, prior risks and preferences. This analysis will focus particularly on the frequency, clinical relevance, costs, and psychological and physical morbidity associated with detection of extracolonic lesions by CT colonography.
Recruitment commenced in March 2004 and at the time of writing (July 2007) 5025 patients have been randomised. A lower than expected prevalence of end-points in the barium enema sub-trial has caused an increase in sample size. In addition to the study protocol, we describe our approach to recruitment, notably the benefits of extensive piloting, the use of a sham-randomisation procedure, which was employed to determine whether centres interested in participating were likely to be effective in practice, and the provision of funding for dedicated sessions for a research nurse at each centre to devote specifically to this trial.
Current Controlled Trials ISRCTN95152621.
用于调查有结直肠癌症状患者的标准全结肠检查方法是钡灌肠和结肠镜检查。结肠镜检查是参考检查方法,但技术难度大、资源消耗多且伴有不良事件,在老年人中尤为如此。钡灌肠更安全,但对癌症的敏感性降低。CT结肠成像(“虚拟结肠镜检查”)是一种更新的替代方法,可能兼具对癌症的高敏感性以及安全性和患者可接受性。SIGGAR试验旨在确定与这项新技术相关的诊断效能、可接受性和经济成本。
SIGGAR试验是一项多中心随机对照试验,比较CT结肠成像与标准检查方法(钡灌肠或结肠镜检查,后者由临床医生个人偏好决定)。将确定对结直肠癌和直径1厘米及以上结肠息肉的诊断效能,以及每种诊断检查相关的生理和心理发病率,后者通过基于定性访谈编制的问卷来确定。将确定每种诊断检查做出诊断或排除诊断的经济成本,试验信息和来自文献的其他数据将用于构建模型,以总结不同年龄、既往风险和偏好的患者检测重大结肠肿瘤的替代方法的健康影响和成本。该分析将特别关注与CT结肠成像检测结肠外病变相关的频率、临床相关性、成本以及心理和生理发病率。
招募工作于2004年3月开始,在撰写本文时(2007年7月)已有5025名患者被随机分组。钡灌肠子试验中终点事件的患病率低于预期,导致样本量增加。除了研究方案,我们还描述了招募方法,特别是广泛预试验的益处、采用假随机程序(用于确定有兴趣参与的中心在实际操作中是否可能有效)以及为每个中心的研究护士提供专门用于该试验的资金。
当前受控试验ISRCTN95152621。